Bone Therapeutics
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more
Bone Therapeutics (0R55) - Net Assets
Latest net assets as of June 2025: €-23.60 Million EUR
Based on the latest financial reports, Bone Therapeutics (0R55) has net assets worth €-23.60 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.50 Million) and total liabilities (€28.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-23.60 Million |
| % of Total Assets | -524.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -906.29% |
| 10-Year Change | -195.25% |
| Growth Volatility | 4510.51 |
Bone Therapeutics - Net Assets Trend (2011–2024)
This chart illustrates how Bone Therapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bone Therapeutics (2011–2024)
The table below shows the annual net assets of Bone Therapeutics from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-26.81 Million | -18.08% |
| 2023-12-31 | €-22.70 Million | -826.79% |
| 2022-12-31 | €3.12 Million | +146.18% |
| 2021-12-31 | €-6.76 Million | -303.46% |
| 2020-12-31 | €3.33 Million | +62.35% |
| 2019-12-31 | €2.05 Million | -54.40% |
| 2018-12-31 | €4.49 Million | +88.46% |
| 2017-12-31 | €2.38 Million | -84.39% |
| 2016-12-31 | €15.27 Million | -45.75% |
| 2015-12-31 | €28.15 Million | +396.75% |
| 2014-12-31 | €-9.48 Million | -15155.56% |
| 2013-12-31 | €63.00K | -97.61% |
| 2012-12-31 | €2.64 Million | -30.80% |
| 2011-12-31 | €3.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bone Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3149300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €8.57 Million | % |
| Other Comprehensive Income | €-74.00K | % |
| Other Components | €6.01 Million | % |
| Total Equity | €-25.07 Million | 100.00% |
Bone Therapeutics Competitors by Market Cap
The table below lists competitors of Bone Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Song Da 505 JSC
VN:S55
|
$24.19K |
|
CORONATION FD MANAG
BE:N8C
|
$24.23K |
|
Keystone Law Group PLC
LSE:KEYS
|
$24.23K |
|
DAR ES SALAAM STOCK EXCHANGE PLC
DSE:DSE
|
$24.24K |
|
LREN3F
SA:LREN3F
|
$24.11K |
|
Altitude International Holdings Inc
PINK:ALTD
|
$24.11K |
|
UACJ Corp
OTCMKTS:UACJF
|
$24.10K |
|
Union Financial Corporation
PINK:UFCP
|
$24.08K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bone Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -22,912,000 to -25,074,000, a change of -2,162,000.
- Net loss of 4,768,000 reduced equity.
- Other comprehensive income decreased equity by 54,001.
- Other factors increased equity by 2,660,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.77 Million | -19.02% |
| Other Comprehensive Income | €-54.00K | -0.22% |
| Other Changes | €2.66 Million | +10.61% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Bone Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | €0.76 | €0.00 | x |
| 2013-12-31 | €0.02 | €0.00 | x |
| 2014-12-31 | €-2.80 | €0.00 | x |
| 2015-12-31 | €4.26 | €0.00 | x |
| 2016-12-31 | €2.23 | €0.00 | x |
| 2017-12-31 | €0.35 | €0.00 | x |
| 2018-12-31 | €0.59 | €0.00 | x |
| 2019-12-31 | €0.21 | €0.00 | x |
| 2020-12-31 | €0.28 | €0.00 | x |
| 2021-12-31 | €-0.13 | €0.00 | x |
| 2022-12-31 | €0.03 | €0.00 | x |
| 2023-12-31 | €-0.17 | €0.00 | x |
| 2024-12-31 | €-0.11 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bone Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-656.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -139.89% | 0.00% | 0.00x | 5.47x | €-3.95 Million |
| 2013 | -6474.60% | 0.00% | 0.00x | 203.35x | €-4.09 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | €-4.79 Million |
| 2015 | -50.25% | 0.00% | 0.00x | 1.79x | €-16.96 Million |
| 2016 | -85.06% | 0.00% | 0.00x | 2.53x | €-14.52 Million |
| 2017 | -535.12% | -31102.44% | 0.00x | 10.56x | €-12.99 Million |
| 2018 | -316.59% | -1421.80% | 0.04x | 5.73x | €-14.67 Million |
| 2019 | -510.79% | 0.00% | 0.00x | 10.93x | €-10.67 Million |
| 2020 | -359.10% | -1194.00% | 0.04x | 7.47x | €-12.27 Million |
| 2021 | 0.00% | -315.38% | 0.02x | 0.00x | €-717.00K |
| 2022 | -57.88% | -689.53% | 0.01x | 8.32x | €-2.39 Million |
| 2023 | 0.00% | -5299.82% | 0.06x | 0.00x | €-26.49 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.26 Million |
Industry Comparison
This section compares Bone Therapeutics's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bone Therapeutics (0R55) | €-23.60 Million | -139.89% | N/A | $24.13K |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |